Animal Models of Preeclampsia

Eduardo Podjarny, Gyorgy Losonczy, and Chris Baylis

There have been many attempts to produce animal models that mimic the hypertensive disorders of pregnancy, especially preeclampsia, but most are incomplete when compared to the full spectrum of the human disease. This review assesses a number of these models, organized according to the investigators attempt to focus on a specific pathogenic mechanism believed to play a role in the human disease. These mechanisms include uterine ischemia, impairments in the nitric oxide system, insulin resistance, overactivity of the autonomic nervous and/or renin-angiotensin systems, activation of a systemic inflammatory response, and most recently, activation of circulating proteins that interfere with angiogenesis. In addition a model of renal disease that mimics superimposed preeclampsia is discussed. Defining these animal models should help in our quest to understand the cause, as well as to test preventative and therapeutic strategies in the management of these hypertensive disorders of pregnancy.

Semin Nephrol 24:596 – 606 © 2004 Elsevier Inc. All rights reserved.

KEYWORDS hypertension, proteinuria, glomerular endotheliosis, intrauterine growth retardation

Preeclampsia, the most frequent, serious, hypertensive complication of pregnancy, occurs spontaneously only in women and higher apes.1 The disorder is caused by pregnancy and cured by delivery and has an overall incidence of 5% to 7%,2 although risk factors such as multiple pregnancy, extremes of maternal age, family history, essential hypertension, and renal disease increase its occurrence. The maternal symptoms of preeclampsia result from suppression of the normal physiologic responses to pregnancy and include generalized vasoconstriction; increased responsiveness to vasoconstrictors, increased blood pressure (BP), increased capillary permeability, sudden severe edema, decreases in plasma volume, increased intravascular coagulation, reductions in organ perfusion, decreases in glomerular filtration rate (GFR), proteinuria, widespread vascular endothelial damage including glomerular endotheliosis and intrauterine growth restriction (IUGR).2 The primary defect is thought to originate at the maternal-fetal interface in association with reduced placental perfusion, leading to fetoplacental ischemia. Placental (but not fetal) tissue is required because preeclampsia occurs in women with hydatiform mole.3 It is believed that the ischemic placenta produces a circulating agent that causes widespread dysfunction of the maternal vascular endothelium,4 leading to the various systemic manifestations of preeclampsia. Thus, an ideal animal model to study pathogenesis, prevention, and treatment should incorporate as much of the earlier-described factors as possible.

There have been numerous attempts to generate animal models of preeclampsia, many of which have been unsuccessful. For example, although essential hypertension is a risk factor for development of preeclampsia in women, pregnancy is powerfully antihypertensive when superimposed on a variety of models of established hypertension in rats, whether genetic or experimentally induced.5-7 In rats with various forms of underlying renal disease, pregnancy often improves renal function8 and only in one situation (passive Heymann nephritis; a model of membranous glomerulonephritis) is renal function acutely worsened by the pregnancy.9 Below, we discuss the more promising animal models of preeclampsia that are currently in use and evaluate their strengths and weaknesses.

The Uteroplacental Ischemia Model of Preeclampsia

This model is based on the primary defect believed to trigger preeclampsia in women. During normal human pregnancy,
blood flow to the uterus increases, up to approximately 25% of the cardiac output by late pregnancy.10 Dilation of the spiral arteries during the first trimester reduces uteroplacental vascular resistance and increases uteroplacental blood flow.11 In women destined to develop preeclampsia, uteroplacental blood flow is reduced by 50% to 70%.12

In 1939, Ogden et al13 tested the hypothesis, first suggested by Young14 in 1914, that uteroplacental ischemia can induce hypertension in pregnant animals. They clamped the abdominal aorta of anesthetized dogs to induce acute reductions of approximately 50% in uteroplacental perfusion pressure. The BP increased by approximately 25 mm Hg in pregnant dogs within minutes and returned to baseline on release of the clamp, without changing in nonpregnant dogs. Adaptations of this technique subsequently have been used by others.13,15,16 Woods and Brooks15 used conscious pregnant dogs and showed that when abdominal aortic pressure was reduced by approximately 40%, systemic BP rapidly increased and remained high until aortic occlusion was stopped, when BP returned to baseline levels. These effects were independent of angiotensin II whereas cyclooxygenase inhibition and thromboxane A2/prostaglandin H2 receptor blockade prevented the pressor response to reductions in uteroplacental perfusion pressure.16 Later studies in pregnant rabbits17–19 and rats,20 showed that agonists of the thromboxane A2/prostaglandin H2 receptors are more potent hypertensive substances than in nonpregnant controls, a finding that, together with that of Woods,16 supports a role for thromboxane A2 as a potential mediator of preeclamptic hypertension. Abitol et al also observed marked increases of BP in conscious dogs in response to chronic uteroplacental ischemia,21 although BP was very variable in controls. Proteinuria was seen in 50% of the animals and endothelial cell swelling and subendothelial electron-dense deposits were present, as were placental infarcts.

A number of researchers have investigated the impact of chronic reductions in uteroplacental perfusion pressure during pregnancy in a variety of other species. In the pregnant rabbit, aortic clamping increased BP within 24 hours and fetal compromise, proteinuria, glomerular endotheliosis, and intracapillary fibrinoid deposition were seen.22 In conscious rabbits,23,24 substantial increases in BP were seen at 1 and 7 days after aortic constriction, as well as increased α-adrenergic tone, decreased plasma angiotensin II concentration with no change in plasma prostanoids. Platelet count decreased suggesting activation/consumption of platelets and mesangial fibrin deposition, proteinuria, placental necrosis, and IUGR also were seen. This hypertension was independent of the renin-angiotensin system.

Aortic constriction in the rat leads to hypertension and proteinuria in pregnancy.25 This model was adapted by Alexander et al,26 who used constriction of the lower abdominal aorta as well as both ovarian arteries (to prevent a compensatory increase in placental blood flow) and these investigators also observed hypertension, proteinuria, and decrements in renal function in pregnant but not virgin rats. In addition, endothelial dysfunction and IUGR were seen as well as increased renal expression of preproendothelin and increased thromboxane. Again, this model of hypertension was independent of the renin-angiotensin system.26–29

In contrast, in the conscious pregnant sheep, stepwise reductions in uterine blood flow, down to approximately 20% of normal, had no effect on BP although fetal hypoxia developed.30 Leffler et al31 also reported no change in BP in the conscious pregnant sheep when uteroplacental perfusion pressure was markedly reduced and pregnancy ended in abortion. In contrast, when pregnant ewes were fed a high salt diet (∼8 × normal intake), BP increased slowly and substantially and some hypertensive pregnant ewes developed convulsions while all had reduced urine volume and exhibited respiratory distress caused by pulmonary edema. Salt loading or reductions in uteroplacental perfusion pressure alone caused no adverse effects in either pregnant or nonpregnant sheep.31

Studies in the rhesus monkey32 suggested that BP increased after reductions in uteroplacental perfusion pressure although only one sham-operated control was studied. Combs et al33 and Zhou et al34 made longitudinal measurements of BP in the conscious, chronically instrumented rhesus monkey, for 4 weeks after reduction of the uterine perfusion pressure in late pregnancy. Most of the pregnant monkeys became hypertensive. However, Zhou et al34 also reported an increased depth of decidual, vascular, and myometrial trophoblast invasion, which contrasts to women with preeclampsia in whom uteroplacental ischemia is associated with shallow trophoblast invasion resulting in the failed dilation of the spiral arteries.35 In pregnant primates (Papio anubis), approximately 60% reduction of aortic flow on day 100 of the 160 days of pregnancy resulted in an approximately 30% increase in BP at term (measured under anesthesia), while renal vascular resistance also was increased.35 Furthermore, the pregnancy-induced expansion of the plasma volume was delayed, some monkeys developed proteinuria, and IUGR was seen, as well as an increased incidence of intrauterine fetal death. Plasma renin activity was reduced, similarly to human preeclampsia, and hyperuricemia also developed.36

An alternate method to reduce uterine blood flow is by occlusion and/or banding of the arteries supplying the uterus.37 In dogs, the maneuver resulted in a gradual increase in BP and proteinuria after the animals had become pregnant.38 Progressive and marked increases in BP occurred over the second and third trimester. Although this is an impressive longitudinal study, nonpregnant animals were not included as controls. Similarly banded rats and rabbits failed to develop any symptoms during pregnancy39 and in the rhesus monkey, no hypertension or proteinuria was observed, although fetal loss was increased after the banding of the uterine arteries.40 Cavanagh et al41,42 were successful in inducing the major symptoms of preeclampsia in baboons by using this technique.

Overall, it does appear that aortic constriction during pregnancy leads to hypertension in a variety of species. Whether this is entirely or partly caused by reductions in
uteroplacental perfusion pressure is less clear because the more selective method of reducing uterine blood flow is much less reproducible as a model of hypertension in pregnancy. Aortic constriction per se may have different hemodynamic consequences (e.g., on cardiac output, sympathetic nervous system, sympathetic nervous system, and so forth) in pregnant versus nonpregnant animals. Thus, clear experimental proof for uteroplacental ischemia being a long-term inducer of significant hypertension is still lacking. There is evidence from animal studies that reductions in uteroplacental perfusion pressure cause placental ischemia and necrosis with fetal growth retardation and intrauterine fetal death in several species. Furthermore, renal histologic changes reminiscent of preeclampsia can be induced by experimental reductions in uteroplacental perfusion pressure in some species.

**Chronic Nitric Oxide Synthase Inhibition During Pregnancy**

Rather than attempting to reproduce the entire disease, an alternative approach is to examine the maternal manifestations of preeclampsia at the level of the endothelium. Interest has focused on nitric oxide (NO) given the evidence indicating that vascular tone is tonically controlled by shear regulated, locally produced, endothelial NO. Chronic nitric oxide synthase (NOS) inhibition produced dose-dependent sustained hypertension in nonpregnant animals, together with renal vasoconstriction, increased glomerular blood pressure, proteinuria, and glomerular injury. Whether NO plays a role in the gestational vasodilation is less certain. Most animal and clinical evidence argues against a role for NO as the exclusive peripheral vasodilator and the endothelial NOS (eNOS) knock-out mouse exhibited a decrease in BP during pregnancy, to the wild-type value, although others reported further increases of BP in pregnancy in the eNOS knock-out model.

Nevertheless, unlike many other models of hypertension, in which pregnancy is antihypertensive, chronic NOS inhibition produced a dose-dependent hypertension in pregnant rats, maintained through to term (Fig. 1). The chronically NOS-inhibited pregnant rat also exhibited renal vasoconstriction leading to a decrease in GFR (Fig. 1), proteinuria, suppression of the normal volume expansion, and increased maternal and fetal morbidity and mortality in a pattern that resembled preeclampsia. Many subsequent studies confirmed our initial observations. Nevertheless, increased NO may not be responsible for the entire peripheral vasodilation of normal pregnancy, it probably does play a role in some vascular beds, most notably the kidney. In particular, studies from the laboratory of Conrad strongly suggested a primary role for NO-mediated renal vasodilation that is signaled by the ovarian hormone relaxin and requires activation of the endothelin type B receptor. Our original studies reported that NO was necessary for the midterm renal vasodilation of pregnancy, although a recent publication by Danielson and Conrad suggested that vaso-dilatory prostaglandins can be recruited to compensate and maintain the midterm increase in GFR despite chronic NOS inhibition. This suggestion raised the issue of completeness of NOS inhibition and we recently repeated the studies of Danielson and Conrad but used a larger dose of NOS inhibitor, given for a longer duration, and found that the midterm increase in GFR was prevented completely and acute administration of the cyclooxygenase inhibitor indomethacin produced insignificant further renal vasoconstriction.

Thus, chronic NO deficiency in pregnancy led to certain manifestations resembling preeclampsia. Given that preeclamptic symptoms have been difficult to produce in the rat, this model has been useful in suggesting an important role for
NO deficiency in preeclampsia. The usefulness of the model is somewhat limited, however, because this involves manipulation of an end point whose resemblance to preeclampsia may be fortuitous.

Adriamycin Nephropathy Model

A single dose of adriamycin given to the nonpregnant rat produces an experimental model of nephropathy with proteinuria, hypertension, and, eventually, chronic renal failure. Micropuncture studies showed that glomerular blood pressure remained normal, indicating that glomerular hypertension was not required for the development of glomerular injury.

Because underlying renal disease is a risk factor for preeclampsia we investigated the impact of superimposed pregnancy in a rat model of adriamycin nephropathy (AN), using a dose of adriamycin (3 mg/kg, intravenously) that had minimal impact on BP, renal function, and renal histology in virgin females 5 weeks after administration. In contrast, term pregnant rats (also studied 5 wk after induction of AN) developed hypertension, heavy proteinuria, a relative decrease in GFR, and an augmented glomerular thromboxane B2/prostaglandin E2 ratio. Thus, pregnant rats with AN exhibited some of the manifestations of superimposed preeclampsia, although placental and renal histology was normal. The increased thromboxane B2/prostaglandin E2 ratio was reminiscent of findings in women with pregnancy-induced hypertension and was functionally important because treatment with the TX receptor antagonist Daltroban from midpregnancy decreased BP in pregnant AN rats. These results suggested that adriamycin induced endothelial dysfunction; supported by our observation that pressor responsiveness to administered angiotensin II was restored in AN pregnant rats and that, in vitro, the mesenteric vascular reactivity of pregnant rats with AN showed an exaggerated response to noradrenaline. It was possible to normalize BP by chronic treatment of pregnant AN rats with diltiazem (calcium channel blocker), methyldopa, or L-arginine and all these maneuvers also increased GFR. The proteinuria was diminished by diltiazem (which enhanced glomerular prostaglandin E2 synthesis) and by L-arginine, whereas methyldopa and daltroban had no effect.

These findings suggested a specific role for derangements in intraglomerular vasodilator substances in the pathogenesis of the proteinuria.

Impaired NOS also was implicated in the hypertension because total NO production was reduced in late pregnancy in rats with AN and administration of L-arginine (Fig 2A), the NO synthase substrate, normalized BP in late pregnant rats with AN. Furthermore, acute NOS inhibi-
tion had no effect on BP in late pregnant AN rats whereas a pressor response was seen in normal pregnant or in AN virgin rats. A single dose of adriamycin (ADR) in non-pregnant rabbits caused a rapid deterioration of endothelium-dependent responses with endothelial generation of oxygen radicals via a flavoprotein containing oxido-reductase. Adriamycin was reduced at the reductase domain of the eNOS and thus was positioned to disrupt the balance between NO and superoxide production. A switch is likely to occur to superoxide, peroxynitrite, and hydrogen peroxide production; potent oxidants implicated in severe vascular pathologies and decreased synthesis of NO.

Whether these acute actions of ADR may affect eNOS bioavailability during pregnancy remains unknown.

The AN model resembles preeclampsia in women in that the maternal symptoms disappear soon after delivery, suggesting that all the systemic and renal derangements are functional in origin. However, the situation is different after 2 pregnancies. At the end of the second pregnancy, BP again was increased and proteinuria also was evident and these remained higher after 7 weeks compared with virgin AN rats (Fig 2B). Histologic examination of the kidneys in AN rats at the end of the second pregnancy and 5 weeks thereafter revealed a significant and irreversible worsening of the renal disease, characterized by a marked mesangial expansion. In contrast, multiple pregnancies have no long-term deleterious effects on BP, renal function, or structure in normal rats, spontaneously hypertensive rats, or in rats with unilateral nephrectomy fed a high-protein diet, and structure was unaffected by multiple pregnancy in rats with 5/6 nephrectomy.

In addition to its usefulness as a model resembling some features of preeclampsia, AN may serve to improve our understanding of mechanisms that lead to irreversible deterioration in renal function as a result of pregnancy.

### Insulin Resistance/Chronic Hyperinsulinemia and Hypertension in Pregnancy

Insulin resistance and hyperinsulinemia are characteristic of normal pregnancy and are maximal in the third trimester. Marked hyperinsulinemia has been described in women with preeclampsia and/or gestational hypertension; although one group suggested that increased insulin resistance and hyperinsulinemia was confined to women with gestational hypertension, and not seen in preeclampsia. However, most investigators report a strong association between hyperinsulinemia and preeclampsia and even 2 months after delivery, preeclamptic women remain insulin resistant and hyperinsulinemic; a finding that may be related to the increased incidence of hypertension in women with a previous history of preeclampsia. The available clinical data also suggest that hyperinsulinemia, insulin resistance, and/or hyperglycemia in early or midpregnancy may be prognostic of later gestational hypertension and/or preeclampsia.

The pathogenic role of insulin resistance/hyperinsulinemia has been evaluated in pregnant rats with chronic hyperinsulinemia induced with sustained-release insulin pellet subcutaneously. As shown in Figure 3, BP increased close to term and pregnant hyperinsulinemic rats also exhibited mildly reduced blood serum glucose levels, hypertriglyceridemia, and a reduced fractional excretion of sodium although urinary protein excretion remained unchanged. The normal increase in GFR (creatinine clearance) seen in pregnant rats was blunted in hyperinsulinemic pregnant rats. Total NO production was diminished and systolic BP correlated directly with serum insulin levels and inversely with total NO production. Treatment with L-arginine normalized BP and increased total NO production and also increased the renal eNOS protein levels. This model also was associated with reduced fetal weight characterized by asymmetric growth retardation (Podjarny, unpublished observations). Treatment with L-arginine improved fetal weight without any change in the levels of serum insulin and glucose.

The fructose-fed rat also develops insulin resistance and a slight increase in blood pressure. When the fructose-fed rat is pregnant, BP is significantly higher than in normal pregnant rats. These results suggest that fructose-induced diabetes could cause hypertension during pregnancy via the insulin-resistance-hyperinsulinemia-link.
Angiogenesis Antagonism and Preeclampsia

Vascular endothelial growth factor (VEGF) plays an important role in angiogenesis and defective angiogenesis may underlie defective placentation, leading to preeclampsia. Alternative splicing of the messenger RNA for one of the VEGF receptors (FLT1) produces a soluble form of FLT1 (sFLT1) that binds with, and antagonizes, both VEGF and placental growth factor (PIGF). Amniotic fluid levels and placental sFLT1 expression are increased in preeclamptic women and Maynard et al have reported that increased circulating levels of sFLT1 are seen in preeclamptic patients.88 Furthermore, these increased levels of sFLT1 lead to decreases in the plasma levels of free VEGF and PIGF,88 and these changes precede, and predict, both the occurrence and severity of preeclampsia89 and may be additive with other risk factors, such as insulin resistance.90

In addition to these clinical observations, Karumanchi’s group have created a novel rat model of preeclampsia, produced by administration of sFLT1-expressing adenovirus that antagonizes the actions of VEGF and PIGF. Administration of the sFLT1-expressing adenovirus (days 8-9 of gestation) produced a dose-dependent hypertension, proteinuria, and glomerular endotheliosis in 16- to 17-day pregnant rats; which is impressive because the pregnant rat is refractory to many hypertensive interventions and rarely exhibits glomerular endotheliosis. The low-dose sFLT1 adenovirus produced levels of circulating sFLT1 seen in preeclamptic women. Further, sFLT1 also produced similar symptoms in nonpregnant rats and administered excess VEGF rescued the sFLT1-infused rat.88 In addition to their angiogenic actions, both VEGF and PIGF cause relaxation when superfused on precontracted rat renal arterioles in vitro, and this vasodilation was blocked by sFLT1,88 perhaps via inhibition of an NO-dependent pathway. Furthermore, although complete knockout of glomerular-specific VEGF is lethal, the heterozygous podocyte-specific VEGF mouse developed in the laboratories of Dr. Quaggin developed proteinuria and glomerular endotheliosis.91

This new model has been developed based on sound predictions from clinical observations. The fact that the hypertension, proteinuria, and glomerular endotheliosis are all reproduced by VEGF/PIGF antagonism suggest that the
primary cause of the maternal manifestations of preeclampsia may be identified.

**Sympathetic Nervous System and Preeclampsia**

Stress has been implicated in an increased incidence of preeclampsia and IUGR in pregnant women92,93 and although the sympathetic output is increased moderately during normal pregnancy it is increased markedly in women with preeclampsia and reverts to normal after delivery.94,95 Studies in rats suggest that increased sympathetic nervous system activity may play a causal role in inducing a preeclampsia-like syndrome. Chronic stress induced by intermittent noise and overpopulation in the cage caused decreased weight gain, higher BP, endothelial dysfunction, mild proteinuria, and IUGR when compared with nonstressed pregnant animals. These changes were associated with an increased fetal adrenal weight (index of chronic stress).96 Sympathetic hyperstimulation in pregnant rats (by stimulation of the celiac ganglion with bacterial lipopolysaccharide or potassium chloride) induced a hemolysis-elevated liver enzymes–low platelet–like syndrome associated with increased plasma catecholamines.97 Chronic, local, cold stimulation of paws also induced a preeclampsia-like syndrome in pregnant rats in association with increased levels of plasma norepinephrine compared with normal pregnant rats and nonpregnant rats.98 A decrease in trophoblast invasion, congestion, and fibrinoid deposits of the labyrinth also were found in the placenta of the cold, stressed, pregnant rats along with increased intrauterine fetal death and IUGR.

All of these models, which share clinical similarities with preeclampsia, may contribute to a better understanding of the interrelationship between increased sympathetic activity and endothelial and placental dysfunction in the pathogenesis of preeclampsia.

**Renin Angiotensin System and Preeclampsia**

There are striking modifications in the renin angiotensin system in normal pregnancy, with high levels of circulating prorenin, renin, angiotensinogen, and angiotensin II (ANGII), together with a marked blunting of the pressor actions of ANGII. In preeclamptic patients, the levels of prorenin, renin, angiotensinogen, and ANGII are all lower than in normal pregnancy and the vascular responsiveness to ANGII is restored.99 Some (but not all) groups have reported that certain polymorphisms in the angiotensinogen gene increase the risk for preeclampsia.99 and a recent study reported the presence of agonistic autoantibodies to ANGII in all women with preeclampsia.99

Overexpression of angiotensinogen led to higher baseline and pregnancy BP that was amplified in the presence of a double mutant, eNOS knock-out and angiotensinogen overexpression model (45). A transgenic mouse model was created with females expressing human angiotensinogen that developed hypertension, proteinuria, and glomerular enlargement only during pregnancy and only when mated with males expressing the human renin.100 A similar model was developed in the rat with similar results.101 Although these models are of interest, they may not be relevant to humans because in the rodents, the hypertension and other pathologies were associated with increased renin and angiotensin levels, whereas in preeclamptic women the various components of the renin angiotensin system are down-regulated versus normal pregnancy.

**Inflammatory Models**

Normal pregnancy has been characterized as an inflammatory state activated by placental debris, with preeclampsia representing an extreme.102 Inflammatory cytokines, produced by the placenta, are more abundant in preeclamptic than normal pregnancy.103 Markers of oxidative stress are increased in the placenta of women with preeclampsia and nitrotyrosine staining (a marker of peroxynitrite, a highly reactive toxic molecule), has been found in the preeclamptic placenta.104,105 In normal placenta, there is an adequate concentration of L-arginine, which permits normal eNOS activity to form NO. In preeclampsia, a lower than normal L-arginine concentration is caused by arginase II overexpression.106 This, together with the high oxidant state induces eNOS uncoupling with increased generation of reactive oxygen species, more peroxynitrite synthesis, and further oxidative stress.107 In pregnant mice, there is a switch from anti-inflammatory to pro-inflammatory cytokines in response to lipopolysaccharide challenge.108 In the rat, injection of an ultra low dose of lipopolysaccharide caused increased BP, proteinuria, low platelet count, and glomerular thrombosis only in pregnancy.109 Furthermore, pregnant rats given lipopolysaccharide developed glomerular thrombosis secondary to NO substrate limitation, indicated by plasma arginine levels decreasing to near zero. In contrast, the same dose of lipopolysaccharide in nonpregnant rats produced only approximately 50% decrements in plasma L-arginine, greater NO generation, and no glomerular thrombosis, thus pregnant females are particularly susceptible to development of L-arginine deficiency.110 Intermittent perfusion of the placenta, secondary to reduced trophoblast invasion (as seen in preeclampsia), may cause increased secretion of the inflammatory mediator tumor necrosis factor α, and that may contribute to the activation of maternal endothelial cells that characterizes preeclampsia.111 In fact, direct administration of tumor necrosis factor α resulted in a preeclamptic-like response in rats in association with a reduction in NOS abundance112 as well as amplified vascular contraction and blunted NO vascular relaxation in isolated vessels.113 Circulating tumor necrosis factor α level are correlated tightly to
measures of insulin resistance in pregnant women, suggesting that inflammation and worsening of insulin resistance may act synergistically in the derangements seen in preeclampsia.

**Other Models**

Starvation during late pregnancy produced a model of toxemia in the sheep and guinea pig with proteinuria, renal pathology, and placental ischemia; however, hypertension was not a common feature of this model. Because starvation does not cause preeclampsia in women, this model is probably of limited use. Calcium deficiency has been implicated as causal in essential hypertension and preeclampsia and dietary calcium restriction increased BP in the pregnant rat and the ewe, in the case of twin pregnancy. However, a recent multicenter National Institutes of Health study revealed no protective effect of calcium supplementation in the development of preeclamptic symptoms, which decreases enthusiasm for this model.

**Summary**

A number of animal models have been identified that resemble some aspects of preeclampsia in normal women. Some of the maternal symptoms of preeclampsia can be produced by uterine ischemia although no quadriped spontaneously exhibits this disease. It may be that the combination of upright posture and uteroplacental ischemia are necessary for manifestation of the full syndrome. Chronic NOS inhibition in rats produces a pattern of change that resembles the symptoms of preeclampsia, and the preeclamptic-like response of rats with adriamycin nephropathy, and hyperinsulinemia is associated with endothelial dysfunction. The activation of stress responses and the sympathetic nervous system also results in some preeclamptic-like symptoms as does activation of endothelial inflammation. The VEGF antagonist model is also exciting and has reinforced the clinical data highlighting the importance of high free circulating levels of VEGF and PI GF in the maternal responses to pregnancy. In fact, of all the animal models of preeclampsia, the sFLT1 shows the greatest promise because, in addition to the hypertension and proteinuria, it is the only animal model with clearly shown glomerular endotheliosis.

These models are definitely of use in preeclampsia research but because this disease only occurs spontaneously in primates, the definitive studies on preeclampsia will, of necessity, be clinical.

**References**

pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension 37:1191-1193, 2001


70. Podjarny E, Pomeranz A, Rathaus M, et al: Effect of L-arginine treat-


Redman CW, Sargent IL: Pre-eclampsia, the placenta and the maternal systemic inflammatory response—a review. Placenta 24A:S21-S27, 2003 (suppl)


Redman CW, Sargent IL: Pre-eclampsia, the placenta and the maternal systemic inflammatory response—a review. Placenta 24A:S21-S27, 2003 (suppl)


Kirwan JP, Hauguel-De Mouzon S, Lepercq J, et al: TNF is a predictor
115. McCarron DA, Morris C, Cole C: Dietary calcium and human hyper-
116. Izumi A, Minakami H, Sato I: Calcium to creatinine ratio in spot urine 
samples in early pregnancy and its relation to the development of 
preeclampsia. Metabolism 46:1107-1108, 1997
117. Belizan JM, Pineda O, Sainz E: Rise of blood pressure in calcium 
118. Prada JA, Tsang RC, Clark KE: Hypocalcemia and pregnancy-induced 
hypertension produced by low-calcium diet. Hypertension 23:695-
702, 1994
119. Sibai BM, Ewell M, Levine RJ: Risk factors associated with preeclampsia 
in healthy nulliparous women: The calcium for preeclampsia preven-
tion (CPEP) study group. Am J Obstet Gynecol 177:1003-1010, 
1997
120. Podjarny E, Baylis C, Losonczy G: Animal models of Preeclampsia. 
Semin. Perinatol 23:2-13, 1999